REGN250103C625000
- 0.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Regeneron Expands Eye Care Focus With Oxular Buyout
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
Regeneron Pharmaceuticals' (NASDAQ:REGN) Investors Will Be Pleased With Their Decent 89% Return Over the Last Five Years
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Regeneron Pharmaceuticals (NASDAQ:REGN) Could Easily Take On More Debt
The USA FDA has revoked the emergency use authorization for four COVID-19 antibody drugs.
On December 24, Gelonghui reported that the USA Food and Drug Administration (FDA) has revoked the emergency use authorization for four COVID-19 antibody drugs, including Eli Lilly and Co's bebtelovimab, AstraZeneca's Evusheld, GlaxoSmithKline's sotrovimab, and Regeneron's REGEN-COV. The FDA stated in a letter earlier this month that the shelf life of these drugs has expired, and due to the spread of non-susceptible variants, they have not been authorized for patient use for more than a year. According to the FDA, the four companies mentioned above do not intend to continue providing the relevant products in the USA and will notify customers and suppliers.
Express News | US FDA: Revoked Emergency Use Authorization for Regeneron's Regen-Cov as of Dec 13 - Website
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
CCORF Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,152
Jefferies Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $950 From $1,190, Keeps Outperform Rating
Regeneron Reports Positive Results for Two Anti-coagulant Drugs
Express News | Regeneron Pharmaceuticals Inc - Regn7508 and Regn9933 Evaluated for Thrombosis Control
Regeneron to Advance Two Factor XI Antibodies Into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
Regeneron Pharmaceuticals Shares Are Trading Higher After the Company Announced Its QUASAR Trial Investigating EYLEA HD Met Its Primary Endpoint for the Treatment of Patients With Macular Edema.
Regeneron Says Phase 3 Trial of Higher Dose Eye Drug Eylea HD Meets Primary Target